Shelston IP is very pleased to announce the following promotions from 1 July 2019. Congratulations to Allira Hudson-Gofers, Duncan Longstaff and Michael Deacon, Shelston IP’s newly appointed Principals. Congratulations also goes to Jennifer Enmon, Nathan Sinclair, Serena White, Danielle Spath and Jessica Chadbourne for their promotions. This is well deserved recognition for their hard work and dedication shown towards their IP practice and clients each day.
Steps are currently being taken by the United States congress to address the issue of patent eligible subject matter that has plagued the United States patent system in recent years. How we got here? There is no question that United States Supreme Court decisions such as Mayo Collaborative Services v Prometheus Laboratories Inc, 566
Let the Petitioner Beware: Clearing a path by proactively challenging patents in an IPR may result in a lack of standing to appeal an adverse decision
A recent decision by the United States Federal Circuit (AVX Corporation v Presidio Components, Inc (Fed Cir, No 2018-1106, 13 May 2019)) has clarified the requirements for standing to appeal from an inter partes review (“IPR”) before the Patent Trial and Appeal Board (“the Board”), but has left open the issue of estoppel. AVX
IAM Patent 1000: The World’s Leading Patent Professionals 2019 results have been announced. Shelston IP have again been Highly Recommended for their patent prosecution. Those who have been singled out, are to be congratulated. “Shelston IP is head and shoulders above the rest, for its holistic service and deep reserves of knowledge. The team
On May 1, Japan entered a new era, known as Reiwa, following the abdication of Emperor Akihito, and, consequently, ending the Heisei era. You may be asking, “What does this have to do with Japanese patent numbers?”, and these days the answer is “not much”, but that hasn’t always been the case. Prior to
The requirement that a patent specification sufficiently enables the subject matter of the claims is particularly relevant to pharmaceutical inventions and can be a hurdle for innovators even if a claimed invention is deemed novel and inventive. In the absence of any prior art, the claimed invention can fail the enablement requirement if it is